Cholesterol Screening and Management in Children and Young Adults Should Start Early-NO!

Department of Pediatrics, Santa Clara Valley Medical Center, San Jose, California. .
Clinical Cardiology (Impact Factor: 2.59). 11/2012; 35(11):665-8. DOI: 10.1002/clc.22075
Source: PubMed


In 2011, an expert panel from the National Heart, Lung, and Blood Institute released recommendations for universal lipid screening and treatment of high cholesterol in children. There is no evidence that universal screening will help children lead longer, healthier lives. These recommendations will, however, fuel the epidemic of overtreatment that is currently threatening our healthcare system and our patients.
The authors have no funding, financial relationships, or conflicts of interest to disclose.

Download full-text


Available from: Rita Redberg, Feb 09, 2015
15 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease (CVD) remains the leading cause of death and morbidity in our society. One of the major risk factors for CVD is hypercholesterolemia. Hypercholesterolemia in children can be caused by a hereditary disorder or can be secondary to other diseases or drugs. In order to prevent CVD later in life, children with hypercholesterolemia should be identified and treated as early as possible. Currently, several different screening strategies have been developed, using either universal screening or case finding to search for children at risk. Once those children are identified, the first step in treatment is lifestyle adjustment. If cholesterol levels remain elevated, the drugs of first choice are statins. Other pharmacological options are ezetimibe or bile acid sequestrants. These agents have all proven to be safe and effective in lowering low-density lipoprotein cholesterol levels and improving surrogate markers of CVD. However, there is a need for long-term follow-up studies to answer the question as to whether it is safe to initiate treatment at a young age to prevent CVD later in life.
    Paediatric Drugs 01/2014; 16(2). DOI:10.1007/s40272-013-0060-2 · 1.98 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Overdiagnosis occurs when a true abnormality is discovered, but detection of that abnormality does not benefit the patient. It should be distinguished from misdiagnosis, in which the diagnosis is inaccurate, and it is not synonymous with overtreatment or overuse, in which excess medication or procedures are provided to patients for both correct and incorrect diagnoses. Overdiagnosis for adult conditions has gained a great deal of recognition over the last few years, led by realizations that certain screening initiatives, such as those for breast and prostate cancer, may be harming the very people they were designed to protect. In the fall of 2014, the second international Preventing Overdiagnosis Conference will be held, and the British Medical Journal will produce an overdiagnosis-themed journal issue. However, overdiagnosis in children has been less well described. This special article seeks to raise awareness of the possibility of overdiagnosis in pediatrics, suggesting that overdiagnosis may affect commonly diagnosed conditions such as attention-deficit/hyperactivity disorder, bacteremia, food allergy, hyperbilirubinemia, obstructive sleep apnea, and urinary tract infection. Through these and other examples, we discuss why overdiagnosis occurs and how it may be harming children. Additionally, we consider research and education strategies, with the goal to better elucidate pediatric overdiagnosis and mitigate its influence.
    Pediatrics 10/2014; 134(5). DOI:10.1542/peds.2014-1778 · 5.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background/objectives: The increase in overweight and obese children and adolescents may be linked to increased rates of dyslipidaemia. The aim was to assess the prevalence of dyslipidaemia and associated risk factors among the Balearic Islands' adolescent population. Subjects/methods: A random sample (n=362, 143 boys and 219 girls, aged 12-17 years) was interviewed, anthropometrically measured and fasting blood samples taken. According to the 2011 Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents, dyslipidaemia was defined as the presence of one or more of the following levels (mg/dl): total cholesterol (TChol)⩾200, low-density lipoprotein cholesterol (LDL-chol)⩾130, non-high-density lipoprotein cholesterol (non-HDL-chol)⩾145, high-density lipoprotein cholesterol (HDL-chol)<40 and tryglicerides (TG)⩾130. Results: The overall prevalence of borderline-high+high TChol, LDL-chol, non-HDL-chol and TG was 24.3, 10.4, 13.3 and 14.9%, respectively. The TChol prevalence was higher among girls (27.8%) than the boys (19.1%). The overall prevalence of borderline-low+low HDL-chol was 12.2% (boys 20.7%; girls 6.3%). The overall prevalence of dyslipidaemia was 13.7% (boys 14.9%; girls 12.9%). Low HDL-chol levels were the most prevalent dyslipidaemia in boys (6.4%) and high TChol in girls (9.1%). Overweight/obese subjects were more likely to have at least one abnormal lipid concentration (odds ratio (OR): 2.10; 95% confidence interval (CI): 1.06-4.15) and subjects with abdominal obesity were more likely to have at least one abnormal lipid level (OR: 3.17; 95% CI: 1.04-9.66). Conclusions: One in ten Balearic Islands' adolescents has at least one abnormal lipid concentration. Body mass index status and waist-to-height ratio were associated with the prevalence of at least one abnormal lipid level.
    European Journal of Clinical Nutrition 10/2014; 69(6). DOI:10.1038/ejcn.2014.236 · 2.71 Impact Factor
Show more